IWMF

International Waldenstrom's Macroglobulinemia Foundation

Welcome to the 25th IWMF Virtual Educational Forum

Theme

2020 Vision: A World without WM

Carl Harrington
IWMF Chairman of the Board

Where We Planned To Be



Renton,
Washington

IWMF
International Waldenstrom's Macroglobulinemia Foundation

4 Objectives

- What's a Virtual Educational Forum?
- Who's attending the Virtual Ed Forum?
- What to expect
- Theme*: 2020 Vision: A World without WM & the progress we've made*

Dr. Jan Waldenström

IWMF
International Waldenstrom's Macroglobulinemia Foundation

How is a Virtual Ed Forum Different from a Live Forum?

- At your house!
- A lot bigger
- A lot more international
- Shorter

IWMF
International Waldenstrom's Macroglobulinemia Foundation

How is a Virtual Ed Forum Similar to a Live Ed Forum?

- Best way to learn about WM from leading experts
- Great way to learn from exhibitors
- Great way to make connections and friends in the WM community

IWMF
International Waldenstrom's Macroglobulinemia Foundation

How is a Virtual Ed Forum Better than a Live Ed Forum?

- Accessible
- Free (this year)
- Front row seats

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Who's Here?

Check the sign in the Virtual Educational Forum Lobby to see the latest attendee statistics

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Years with WM



- 50+ = 3
- 40+ = 5
- 30+ = 27
- 25-29 = 70
- 20-24 = 234
- 15-19 = 422
- 10-14 = 652
- 5-9 = 1150
- 1-4 = 1170
- Less than 1 Year = 64
- **Total Dx more than 20 Years Ago = 339**

Ages



- 100+ = 2
- 95-99 = 24
- 90-94 = 66
- 80-89 = 581
- 70-79 = 1199
- 60-69 = 857
- 50-59 = 343
- 40-49 = 71
- 30-39 = 10
- 20's = 2

What to Expect:

- Improve your computer skills!
- Learn about WM and the science behind it
- Feel more hopeful about having WM
- Expect to feel that YOU ARE NOT ALONE!

IWMF
International Waldenstrom's Macroglobulinemia Foundation

What to Expect:
Sponsor Exhibitors

Thank you to our 2020
IWMF Virtual Educational Forum sponsors:

BeiGene

CELLECTAR BIOSCIENCES

janssen | PHARMACEUTICAL COMPANIES OF Johnson & Johnson

pharmacyclics®
An AbbVie Company

The Treadway Foundation

X4 PHARMACEUTICALS

IWMF
International Waldenstrom's Macroglobulinemia Foundation

What to Expect:
Our Partners



What to Expect: Speaker Bios

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Meet Your 2020 IWMF Virtual Ed Forum Speakers

Jorge J. Castillo, MD

Dana-Farber Cancer Institute:
Current Treatment Options for WM Including Implications from COVID-19
and
A Look into the Future: New Treatments on the Horizon

Jorge J. Castillo, MD, is Associate Professor at Harvard Medical School and Clinical Director of the Bing Center for Waldenström Macroglobulinemia at Dana-Farber Cancer Institute.

Dr. Castillo was born in Peru and received his medical degree at the Universidad Autonoma Metropolitana in Mexico City. He completed his residency in internal medicine at the University of Massachusetts and his fellowship in hematology and medical oncology at Brown University.

Dr. Castillo specializes in the treatment of Waldenström macroglobulinemia. His research focuses on the various risk factors associated with an increased risk of developing hematologic malignancies. He currently is the principal investigator in a series of innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Dr. Castillo has authored more than 220 peer-reviewed articles and has published his research in The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Blood.

Dr. Castillo is a member of several professional organizations, including the American Society of Hematology, and the Peruvian Society of Hematology (honorary). He regularly contributes to the International Workshop on Waldenström Macroglobulinemia, serving on task forces and scientific program committees for the biennial meeting. He also is an advisor to the Steering Committee for the Latin American Group for the Study of Lymphoma.

Dr. Castillo is a member of the NCCN Multiple Myeloma/Systemic Light Chain Amyloidosis/ Waldenström's Macroglobulinemia Panel.

Dr. Steven Treon, MD, PhD

Dana-Farber Cancer Institute:
News from the WM Front Including an Update on COVID-19

Dr. Treon is the Director of the Bing Center for Waldenstrom's Macroglobulinemia at Dana-Farber Cancer Institute (DFCI), a Professor of Medicine at Harvard Medical School, and Chair of the WM Clinical Trials Group. Dr. Treon earned a BA (Biology), MS (Biochemistry), PhD (Cancer Immunology), and MD with honors from Boston University, and MA from Harvard Medical School. He completed an Internal Medicine residency at Boston University Medical Center, Hematology/ Medical Oncology Fellowship at Massachusetts General Hospital, and post-doctoral training at DFCI.

In 1999, Dr. Treon initiated a WM clinic at DFCI which cares for nearly 2,500 WM patients annually. Using whole-genome sequencing, Dr. Treon's laboratory first identified highly recurring activating mutations in MYD88 and CXCR4 in WM patients and was the first to report that Bruton's tyrosine kinase (BTK) was a downstream target of the MYD88 L265 mutation, resulting in a study leading to the first-ever approval of a drug (ibrutinib) for WM.

Dr. Treon has published extensively on topics in WM and related disorders, with over 300 peer-reviewed original reports, reviews, editorials, and chapters in high-impact journals and textbooks. He has been the principal organizer of the biennial International Workshops on WM since 2000 and the International Patient and Physician Summits since 2003. His scientific work in WM has earned "Best of the American Society of Hematology" designations at the 2011 and 2013 Annual Meetings of the American Society of Hematology. In 2017, Dr. Treon was elected as a fellow to the Royal College of Physicians in London, and in 2018, as a fellow to the American College of Physicians.

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Meet Your 2020 IWMF Virtual Ed Forum Speakers

Stephen M. Ansell, MD, PhD

Mayo Clinic Rochester:
Strategic Research Roadmap: Getting to a World Without WM

Stephen M. Ansell, MD, PhD, is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic in Minnesota. Dr. Ansell currently serves as chair of the Mayo Clinic Lymphoma Disease-Oriented Group and chair of faculty development and recruitment for the Division of Hematology. He joined the staff of Mayo Clinic in 1999 and holds the academic rank of Professor of Medicine, Mayo Clinic College of Medicine and Science.

Dr. Ansell earned his MB, ChB, and PhD degrees at University of Pretoria in Pretoria, South Africa, where he also completed an internship in internal medicine and surgery, a residency in internal medicine, and a fellowship in medical oncology. Dr. Ansell continued his education at University of the Witwatersrand in Johannesburg where he was a registrar in internal medicine. He then came to the United States and completed a residency in internal medicine and then a fellowship in hematology/ oncology at Mayo Clinic.

Dr. Ansell's research focuses on investigating the phenotype and activity of intratumoral T-cells and developing strategies to modulate the T-cell infiltration in B-cell lymphoma.

Tom Hoffmann, MD

IWMF Trustee &
Vice President for Research:
Moderator, Ask the Doctors LIVE

Dr. Hoffmann is a retired cardiovascular and heart transplant surgeon from Little Rock, AR, who now resides in Texas. He received his medical training at the University of Arkansas Medical Center, followed by general surgery training in Louisville, KY, and cardiology training at the University of Texas at San Antonio and at the Heart Institute in Houston with Dr. Denton Cooley.

Dr. Hoffman was diagnosed with WM in 1999 and treated with one course of Rituxan; he is still in remission from that treatment. Dr. Hoffmann served on the IWMF Board of Trustees from 2002-2004 and re-joined the Board in 2018, assuming the position of Vice President for Research. He is an avid outdoorsman and an active participant on IWMF Connect.

IWMF
International Waldenstrom's Macroglobulinemia Foundation

What to Expect: Agenda

IWMF
International Waldenstrom's Macroglobulinemia Foundation

VIRTUAL EDUCATIONAL FORUM
THURSDAY, AUGUST 27, 2020

AGENDA

9:00am.-10:45am. EDT	Visit Virtual Exhibits/Resource Center	
10:45am.-11:00am. EDT	**Welcome & Opening Remarks**	Carl Harrington, IWMF Chair of the Board
	Introduction: Dr. Castillo	Carl Harrington
11:00am.-11:40am. EDT	***Current Treatment Options for Waldenstrom Macroglobulinemia***	Jorge Castillo, M.D.
11:40am.-12:00pm. EDT	**Q&A LIVE with Dr. Castillo** Moderator:	Peter DeNardis, Trustee
12:00pm.-12:15pm. EDT	Break – Virtual Exhibits/Resource Center	
12:15pm.-12:55pm. EDT	***A Look into the Future: Treatments on the Horizon***	Jorge Castillo, M.D.
12:55pm.-1:15pm. EDT	**Q&A LIVE with Dr. Castillo** Moderator:	Peter DeNardis
1:15pm.-1:30pm. EDT	Break – Virtual Exhibits/Resource Center	
	Introduction: Dr. Treon	Guy Sherwood, M.D.
1:30pm.-2:10pm. EDT	***Improving Patient Outcomes through Discovery: Waldenstrom's Macroglobulinemia***	Steven Treon, M.D., Ph.D.
2:10pm.-2:30pm. EDT	**Q&A LIVE with Dr. Treon** Moderator:	Guy Sherwood, M.D.
2:30pm.-5:00pm. EDT	Visit Virtual Exhibits/Resource Center	

IWMF
International Waldenstrom's Macroglobulinemia Foundation

What to Expect: Agenda



IWMF
International Waldenstrom's Macroglobulinemia Foundation

WALK FOR WM and
VIRTUAL EDUCATIONAL FORUM
FRIDAY, AUGUST 28, 2020

AGENDA

8:00am.-9:00am. EDT	Visit Virtual Exhibits/Resource Center	
Walk for WM		
9:00am.-9:05am. EDT	**Kick Off Walk for WM**	Newton Guerin, President & CEO
9:05am.-9:15am. EDT	Total Body Warm-Up	Stacy Kennedy, MPH, RD
9:15am.-10:15am. EDT	***Walk for WM – Ready, Set, Go!***	
10:15am.-10:30am. EDT	Awards/Recognition	Jeremy Dictor, Director of Development and Communications
Virtual Educational Forum		
10:45am.-11:00am. EDT	**Welcome & Opening Remarks**	Newton Guerin, President & CEO
	Introduction: Dr. Ansell	Newton Guerin
11:00am.-11:40am. EDT	***Strategic Research Roadmap: Getting to a World Without WM***	Stephen Ansell, M.D., Ph.D.
11:40am.-12:00pm. EDT	**Q&A LIVE with Dr. Ansell** Moderator:	Peter DeNardis, Trustee
12:00pm.-12:15pm. EDT	Break – Virtual Exhibits/Resources	
	Introduction and Moderator:	Thomas Hoffmann, M.D.
12:15pm.-1:45pm. EDT	***Ask the Doctors - LIVE***	Dr. Stephen Ansell Dr. Jorge Castillo Dr. Steven Treon
1:45pm.-2:00pm. EDT	**Closing Remarks**	
2:00pm.-5:00pm. EDT	Visit Virtual Exhibits/Resource Center	

IWMF
International Waldenstrom's Macroglobulinemia Foundation

What to Expect:
Time for Questions

- Q&A LIVE after each session

- 1 ½ hours tomorrow on “Ask the Doctors” (12:15pm.-1:45pm. EST)

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Global Educational Webinars

- **Dr. Jeffrey Matous***: Getting to Know WM: Basics & Beyond* held on July 22, 2020 and available on-demand
- **Dr. Zachary Hunter**: *Making Sense of the Science of WM* to be held on September 9, 2020
- **Dr. Irene Ghobrial**: *IgM MGUS & Smoldering WM: How Understanding Precursors Can Help in Finding A Cure* to be held on October 14, 2020
- **Dr. Edward Libby**: *Understanding Your Blood & Bone Marrow Test Results* to be held on November 10 or December 12, 2020
- **Neena Kennedy (LLS*)***: *Why Clinical Trials Matter and How to Find the Right One for You* to be held on January 13, 2021

IWMF
International Waldenstrom's Macroglobulinemia Foundation

2020 Vision:
A World without WM



IWMF
International Waldenstrom's Macroglobulinemia Foundation

2020 Vision:

A World without WM - Progress over the last 25 years



IWMF
International Waldenstrom's Macroglobulinemia Foundation

Progress towards a World without WM: Number of Members

	1994 - 1998	NOW
# of Members	21	**24,316**
# of Countries	1	**>80**

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Progress towards a World without WM: Life Expectancy

	1994 - 1998	NOW
Life Expectancy	?	**16-20 years**
	3-5 years	

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Progress towards a World without WM: Treatments

	1994 - 1998	NOW
# of Treatments	4	**41+**

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Progress towards a World without WM:
More Treatments Coming

- Venetoclax
- Acalabrutinib
- Zanubrutinib
- Tirabrutinb
- Ulocuplomab
- Ixazomib
- Daratumumab
- Mavorixafor
- Oprozomib
- Obinutuzumab
- Carfilzomib
- LOXO-3035

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Progress towards a World without WM: IWMF Sponsored Research



The sun never sets on IWMF Research

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Progress towards a World without WM: IWMF Support

	1994 - 1998	NOW
Int'l Affiliates	0	22
Support Groups	0	>65
Languages	1	7+

The sun never sets on IWMF Support

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Getting to A World without WM

- Keep giving
- Participate in clinical trials
- Keep sharing

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Youngest Donor to the IWMF

Miles Harrington

IWMF
International Waldenstrom's Macroglobulinemia Foundation

Introduction: Dr. Jorge Castillo

Current Treatment Options for WM

Jorge J. Castillo, MD
Associate Professor, Harvard Medical School
Clinical Director – Bing Center Clinic
Dana-Farber Cancer Institute
Boston, Massachusetts

IWMF
International Waldenstrom's Macroglobulinemia Foundation